Lyn, Fyn, Syk, BLNK, and PLC-γ2 immunostaining patterns of neoplastic cells in paraffin-embedded biopsies from cases of Hodgkin disease
Case no. . | Lyn . | Fyn . | Syk . | BLNK . | PLC-γ2 . |
---|---|---|---|---|---|
Classical Hodgkin disease | |||||
1 (NS) | (-) | +/- | - | - | - |
2 (NS) | - | (-) | - | - | - |
3 (NS) | - | (-) | - | - | - |
4 (NS) | - | + | - | - | - |
5 (NS) | (-) | + | - | - | - |
6 (NS) | - | (-) | - | - | NT |
7 (NS) | - | (-) | - | - | - |
8 (NS) | -/+ | + | - | - | - |
9 (NS) | + | + | - | - | - |
10 (NS) | - | - | - | - | NT |
11 (NS) | - | + | - | - | - |
12 (NS) | - | - | - | - | - |
13 (MC) | NT | - | - | NT | - |
14 (MC) | - | (-) | - | - | - |
15 (MC) | (-) | (-) | - | - | - |
16 (MC) | - | -/+ | - | - | - |
17 (MC) | + | - | - | - | NT |
18 (MC) | - | - | - | - | - |
19 (MC) | NT | + | - | - | - |
20 (MC) | - | + | - | - | - |
21 (MC) | - | - | - | - | - |
22 (MC) | - | - | NT | - | - |
23 (LR) | - | - | NT | - | - |
24 (LR) | - | -/+ | - | - | - |
25 (LR) | - | + | - | - | - |
26 (LR) | - | - | - | - | - |
Lymphocyte predominance | |||||
1 | + | + | + | + | + |
2 | - | + | + | + | + |
3 | - | + | + | + | + |
4 | - | + | + | + | + |
5 | -/+ | + | + | + | + |
6 | - | + | + | + | + |
7 | + | + | + | + | + |
8 | - | + | + | + | + |
9 | - | + | NT | + | + |
10 | - | + | + | + | + |
11 | - | + | + | + | + |
12 | - | + | + | (-) | + |
13 | - | + | + | + | + |
14 | - | + | + | + | + |
15 | - | +w | +w | +w | + |
16 | - | + | + | +w | + |
17 | - | + | + | + | + |
18 | + | + | +w | +w | NT |
19 | - | + | + | +w | + |
Case no. . | Lyn . | Fyn . | Syk . | BLNK . | PLC-γ2 . |
---|---|---|---|---|---|
Classical Hodgkin disease | |||||
1 (NS) | (-) | +/- | - | - | - |
2 (NS) | - | (-) | - | - | - |
3 (NS) | - | (-) | - | - | - |
4 (NS) | - | + | - | - | - |
5 (NS) | (-) | + | - | - | - |
6 (NS) | - | (-) | - | - | NT |
7 (NS) | - | (-) | - | - | - |
8 (NS) | -/+ | + | - | - | - |
9 (NS) | + | + | - | - | - |
10 (NS) | - | - | - | - | NT |
11 (NS) | - | + | - | - | - |
12 (NS) | - | - | - | - | - |
13 (MC) | NT | - | - | NT | - |
14 (MC) | - | (-) | - | - | - |
15 (MC) | (-) | (-) | - | - | - |
16 (MC) | - | -/+ | - | - | - |
17 (MC) | + | - | - | - | NT |
18 (MC) | - | - | - | - | - |
19 (MC) | NT | + | - | - | - |
20 (MC) | - | + | - | - | - |
21 (MC) | - | - | - | - | - |
22 (MC) | - | - | NT | - | - |
23 (LR) | - | - | NT | - | - |
24 (LR) | - | -/+ | - | - | - |
25 (LR) | - | + | - | - | - |
26 (LR) | - | - | - | - | - |
Lymphocyte predominance | |||||
1 | + | + | + | + | + |
2 | - | + | + | + | + |
3 | - | + | + | + | + |
4 | - | + | + | + | + |
5 | -/+ | + | + | + | + |
6 | - | + | + | + | + |
7 | + | + | + | + | + |
8 | - | + | + | + | + |
9 | - | + | NT | + | + |
10 | - | + | + | + | + |
11 | - | + | + | + | + |
12 | - | + | + | (-) | + |
13 | - | + | + | + | + |
14 | - | + | + | + | + |
15 | - | +w | +w | +w | + |
16 | - | + | + | +w | + |
17 | - | + | + | + | + |
18 | + | + | +w | +w | NT |
19 | - | + | + | +w | + |
NS indicates nodular sclerosis; MC, mixed cellularity; LR, lymphocyte rich; NT, not tested (material not available); -, all tumor cells negative; (-), staining in single tumor cells up to 3%-5% of the tumor cells; -/+, staining in 30% of the tumor cells; +/-, staining in more than 50% of the tumor cells; +, staining in more than 90% of the tumor cells; w, weak staining.